Andelen af patienter, som fik UACR reduceret med mindst 50% fra baseline ved forsøgets slutning var henholdsvis 24, 7% for aliskiren og 12, 5% for placebo.
The proportion of patients who had UACR reduced at least 50% from baseline to endpoint was 24.7% and 12.5% for aliskiren and placebo, respectively.